Merck to End Development of Two Cancer Candidates: Time to Sell?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
The Pharma Letter17h
Merck & Co cuts TIGIT and LAG-3 programs
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Pharmabiz21h
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC
Merck is discontinuing the phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...
Daily21h
Merck discontinues clinical development programs for vibostolimab, favezelimab
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...